Synapse - Larry Norton

Results (760)

A prospective longitudinal study of the impact of adjuvant chemotherapy for breast cancer (BC) on older patients' functional status and quality of life

Meeting Abstract

Hurria, A.; Panageas, K.; Zuckerman, E.; Fornier, M.; D'Andrea, G.; Dang, C.; Moasser, M.; Robson, M.; Seidman, A.; Currie, V.; more...
Breast Cancer Research and Treatment (2005)

Fulltext@MSK | Save

Five year follow-up of INT C9741: Dose-dense (DD) chemotherapy (CRx) is safe and effective

Meeting Abstract

Hudis, C.; Citron, M.; Berry, D.; Cirrincione, C.; Gradishar, W.; Davidson, N.; Martino, S.; Livingston, R.; Ingle, J.; Perez, E.; more...
Breast Cancer Research and Treatment (2005)

Fulltext@MSK | Save

Increased dose-density (DD) is feasible: A pilot study of epirubicin and cyclophosphamide (EC) followed by paclitaxel (T), at 10-11 day interval with filgrastim support, for women with early breast carcinoma (BC)

Meeting Abstract

Fornier, M. N.; Seidman, A. D.; Lake, D.; D'Andrea, G.; Bromberg, J.; Robson, M.; Van Poznak, C. H.; Panageas, K.; Norton, L.; Hudis, C.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Prolonged dose-dense (DD) epirubicin and cyclophosphamide (EC) followed by paclitaxel (T) in breast cancer (BCA) is feasible

Meeting Abstract

Dang, C.; Smith, K.; Lake, D.; Fornier, M.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Troso-Sandoval, T.; Sugarman, S.; Gilewski, T.; more...
Breast Cancer Research and Treatment (2005)

Fulltext@MSK | Save

Preliminary cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/neu overexpressed/amplified breast cancer (BCA)

Meeting Abstract

Dang, C.; Smith, K.; Lake, D.; Fornier, M.; D'Andrea, G.; Seidman, A.; Sklarin, N.; Troso-Sandoval, T.; Sugarman, S.; Gilewski, T.; more...
Breast Cancer Research and Treatment (2005)

Fulltext@MSK | Save

Dose-dense (DO) AC followed by paclitaxel is associated with moderate, frequent anemia compared to sequential (S) and/or less DD treatment: Update by CALGB on breast cancer intergroup trial C9741 with ECOG, SWOG, & NCCTG

Meeting Abstract

Citron, M. L.; Berry, D. A.; Cirrincione, C.; Livingston, R. B.; Gradishar, W.; Perez, E.; Muss, H.; Norton, L.; Winer, E.; Hudis, C.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: Cancer and Leukemia Group B 9344

Journal Article

Sartor, C. L.; Peterson, B. L.; Woolf, S.; FitzGerald, T. J.; Laurie, F.; Turrisi, A. J.; Bogart, J.; Henderson, I. C.; Norton, L.
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: A report of CALGB 9082, SWOG 9114, and NCIC MA-13

Journal Article

Peters, W. P.; Rosner, G. L.; Vredenburgh, J. J.; Shpall, E. J.; Crump, M.; Richardson, P. G.; Schuster, M. W.; Marks, L. B.; Cirrincione, C.; Norton, L.; more...
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save

Dose-dense adjuvant chemotherapy for primary breast cancer

Journal Article

Fornier, M.; Norton, L.
Breast Cancer Research (2005)

Fulltext@MSK | Save

Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients

Journal Article

Dressler, L. G.; Berry, D. A.; Broadwater, G.; Cowan, D.; Cox, K.; Griffin, S.; Miller, A.; Tse, J.; Novotny, D.; Persons, D. L.; more...
Journal of Clinical Oncology (2005)

Fulltext@MSK | Save